中美仿制药研发申报流程.精讲.ppt

Click to edit Master text styles,Second level,Third level,Fourth level,Fifth level,Company Logo,*,Click to edit Master title style,中美仿制药研发和申报流程,涂家生，,Ph.D.,中国药科大学药剂学教授,Tel:[phone],Email:jiashengtu,2011.11,郑州,我国仿制药申报、审评和研发对策,主要内容,中美关于原研药和仿制药的背景,美国仿制药：申报、基于问题的审评和研发对策,展望,1,2,3,4,药物经济学催生美国仿制药制度,美国社会安全制度导致政府赤字严重,SSA,已经破产：如何破局？,降低医疗费用成为必然,Hatch-Waxman,法案出台,美国,FDA,药品注册申请：新药（两类）、仿制药和非处方药申请,3,Ceryak,1984,年后,New Drug Applications,(NDAs),Abbreviated New Drug,Applications(ANDAs),“,Full Reports”of Safety and Efficacy Investigations,Applicant has right of reference to essential investigations?,Duplicate of an already approved product,No safety/efficacy data permitted(only bioequivalence),YES,NO,505(b)(1),505(b)(2),505(j),NDA,的研发和申报,505(b)(1),新药申报资料内容,Index,Summary,Chemistry,Manufacturing and Control,Samples,Methods Validation Package and Labeling,Nonclinical Pharmacology and Toxicology,6.,Human Pharmacokinetics and Bioavailability,7.Microbiology(for anti-microbial drugs only),8.Clinical Data,9.Safety Update report(typically submitted 120 days after the NDAs submission),10.Statistical,11.Case Report Tabulations,12.Case Report Forms,13.Patent Information,14.Patent Certification,505(b)(2):,历史过程,Hatch,Waxman,法案：,1984,Parkman Letter,Phantom ANDA,FDA Draft Guidance for Industry(1999),FDA Response to Citizens Petition(,2003),可以降低研发的费用和审评力量的浪费,505(b,)(2,),的关键,:,可靠性,What is“Reliance”,By whom?,On what?,Reliance and Exclusivity,Market vs.Data Exclusivity,Safety/Efficacy Data vs.CM&C data,FDA Process for Determining Reliance,Who,when and how?,505(b)(2),的意义,介于全创新药物和仿制药之间,具有专利保护，且不存在产权纠纷,和仿制药不同，无替换的要求,应有突破,505(b,)(2,),范围,New,Chemical Entity(,rarely),：我国,1.1-1.3,New dosage,form,：我国,5,类,New dosing,regimen,：我国补充申请,New,strength,：我国补充申请,New route of,administration,：我国,2,类,New,indication,：我国,1.6,505(b,)(,2),情形,New active ingredient(different salt,ester,complex,chelate,clathrate,racemate,or enantiomer of active moiety),New inactive ingredient that requires more than limited confirmatory studies,Rx,OTC switch,New Combination Products,“Generic biologics”,505(b,)(,2),排他性,Exclusivities available for 505(b)(2)products,NCE Exclusivity(5 years),New Product Exclusivity(3 years),Orphan Drug Exclusivity(7 years),Pediatric exclusivity extensions(6 months),Patent Issues,505(b)(2)drugs can have Orange Book-listed patents,and enjoy 30-month stay protection against generic competitors,But,505(b)(2)NDAs may also be blocked by patents on Reference Drugs,505(b)(2),新药的成功例子,NCE,Thalomid(thalidomide)(1998),Marketed unapproved drugs,Levothyroxine(2000),Guaifenesin extended release(2002),Quinine sulfate(2005),New Dosage Form,Tramadol orally disintegrating tablets(2005),Ondansetron oral spray(filed 2006),505(b)(2),新药的例子,New Dosing Regimen,Tramadol extended release tablets(2005),New Strength/Formulation,Antara(micronized fenofibrate caps)(2004)(130 mg is BE to Tricor 200 mg),New Formulation/Inactive Ingredient,Avita(tretinoin gel)(new emollient)(1998),Abraxane(cremaphor-free paclitaxel)(2005),Oxy-ADFoxycodone formulated to reduce drug abuse)(in development),505(b)(2),新药的例子,New Active Ingredient,Pexeva(paroxetine mesylate)(new salt)(2003),New Route of Administration,Emezine(prochlorperazine)(new buccal/transmucosal delivery)(NDA pending),Oral amphotericin-B(pre-clinical),Rx,OTC Switch,Alavert(loratadine)(2002),505(b)(2),新药的例子,“,Generic Biologics”,Omnitrope(rHGH)(2006),Glucagen(glucagon recombinant)(1998),Hyaluronidase(various approvals 2004-05),Fortical(calcitonin salmon recombinant)(2005),*Examples based on publicly available information,FDA NDA,审评过程,FDA,可以使用已有数据用于审评,NDA,吗？,Hatch-Waxman,之前,国会限制,FDA,在审评,NDA,X,时应用,NDA,Y,的数据：,“No,data in an NDA can be utilized to support another NDA without express permission of the original NDA,holder.”,FDA“Finkel Memorandum”(1978,1981),Hatch-Waxman,解除只适合,ANDAs,：,ANDA,process allows,“generic producer of the fully tested drug to rely on the safety and efficacy data of a prior applicant.”,505(b,)(2)does not authorize such data reliance,Merely sets conditions for certain NDAs,Requires“full reports of investigations”establishing safety and effectiveness 21 USC 355(b)(1)(A),(d)(1),美国仿制药,A generic drug product is one that is comparable to an innovator drug product(also known as the reference listed drug(RLD)product as identified in the FDAs list of,Approved Drug Products with Therapeutic Equivalence Evaluations,)in dosage form,strength,route of administration,quality,performance characteristics and intended use.,Generic drug applications are termed“abbreviated”in that they are generally not required to include preclinical(animal)and clinical(human)data to establish safety and effectiveness.,These parameters were established upon the approval of the innovator drug product,which is the first version of the drug product approved by the FDA.,FDA,审评仿制药程序,二、美国仿制药的申报、审评和研发对策,由,FDA,的,OGD,审评,审评方式采用,QbR,申报资料采用,CTD,资料内容也针对问题,Office of Generic Drugs,如何保证审评质量和效率？,Structured Product Labeling(SPL),Makes labeling available on Internet via National Library of Medicine(NLM),Review Efficiencies,Early DMF review,Cluster reviews product specialists,Supplement triaging at team leader level,DBE Truncated Review,Question based Review(,QbR,),Will have a very positive impact,New resources developed,Dissolution Database,Individual Product Bioequivalence Information,Encouraged the use of telephone in review process,Increased the number of 1,st,cycle approvals,Decreased the total number of review cycles,Total time to approval did not increase in spite of increased workload,Dissolution Methods for Drug Products,New!,ben,This guidance contains an,Internet link,to a listing of drug products,each linked in turn to a corresponding bioequivalence recommendation.Clicking on a product name in that list will bring up the,bioequivalence recommendations for that specific product.,Recommendations have been developed for several drugs that are not yet eligible for generic competition(i.e.,newly approved products)and some older products for which information has previously been provided.As,additional recommendations are developed,those will be posted on the Web site,.When this guidance is finalized,the listing will be available through the Agencys Web page.,OFFICE OF GENERIC DRUGS,TABLE OF BIOEQUIVALENCE RECOMMENDATIONS,Active Ingredient,Potency,Dosage Form,Route of Administration,Date Finalized,Almotriptan,Malate,12.5 mg,Tablet,Oral,5/16/2005,Alosetron,1 mg,Tablet,Oral,5/31/2005,Atazanavir,200 mg,Capsule,Oral,3/18/2005,Atomoxetine,60 mg,Capsule,Oral,6/13/2005,Cefditoren,Pivoxil,200 mg,Tablet,Oral,3/18/2005,Dutasteride,0.5 mg,Capsule,Oral,7/5/2005,Eplerenone,50 mg,Tablet,Oral,3/18/2005,Fosamprenavir,Calcium,700 mg,Tablet,Oral,3/18/2005,Memantine,10 mg,Tablet,Oral,7/8/2005,Rosuvastatin,40 mg,Tablet,Oral,3/18/2005,Tadalafil,20 mg,Tablet,Oral,3/18/2005,Vardenafil,HCl,20 mg,Tablet,Oral,4/11/2005,QbR,:,从提出到完善,1/2005 2/2005:,Question-based Review,Drafted,3/2005 4/2005:Division Directors Discussion,5/2005 6/2005:Team Leaders Discussion,7/2005 8/2005:Reviewers Discussion,9/2005 1/2006:Model Pharmaceutical Development Report and Quality Overall Summary,2/2005 12/2005:Discussions with Stakeholders and Upper Management,1/2005 12/2006:Gradual Implementation,1/2007:Full Implementation,QbR,的内涵,Question-based Review is a general framework for a science and risk-based assessment of product quality,Question-based Review contains the important scientific and regulatory review questions to,关键制备工艺及其质控,产品的工艺、处方是否有设计缺陷,强调,QbD,ANDAs Under,QbR,(Continued),Future Generic Applications,generic,sponsors submit generic applications,based on the format of ICH CTD,preferably,electronically,Module 1:Administrative Information,Module 2:Quality Overall Summary and Clinical Summary,Module 3:Quality,Pharmaceutical Development;Quality by Design,Module 4:,Nonclinical,Module 5:Clinical(Bioequivalence),新药申报（,NDA,）,和仿制药申报（,ANDA,）的比较,1.Chemistry,2.Manufacturing,3.Controls,4.Labeling,5.Testing,6.Animal Studies,7.Clinical Studies,8.Bioavailability,NDA requirements,ANDA requirements,1.Chemistry,2.Manufacturing,3.Controls,4.Labeling,5.Testing,6.Bioequivalence,美国仿制药申报,模块,1,包含了管理和处方信息，这个是区域特异的。在美国应包括以下信息：申请书,3674,；专利认证信息；原研药信息，包括,NDA,号、药名和生产商；仿制药和原研药的对比，包括使用条件、有效成分、非有效成分、给药途径、剂型和剂量；环境影响分析；药品说明书（草稿）。,模块,2,模块,2,为概论。它包括药理作用分类，作用模式以及临床适应证。,模块,3,应该包含原料药和制剂相关的化学、生产和质量控制信息,。,FDA,仿制药部（,OGD,）鼓励申请人根据,ICH,对于人用药物的注册技术要求，即通用技术文件（,CTD,）的格式，提交,ADNA,。包括以下模块：,模块,4,模块,4,是关于动物实验的信息，并不是,ANDA,要求的。所以，仿制药申请一般不包含模块,4,。,模块,5,模块,5,是临床研究报告。对于,ADNA,，生物等效性信息应该在这个部分体现，包括：生物等效性研究；体外体内相关性研究；生物分析方法开发。案例报告，包括不良反应事件报告也应包括在此。,OGD QBR,The question based review(QBR)serves as a,general,framework for the CMC assessment of ANDAs that focuses on critical pharmaceutical attributes of product quality.With justification,deviations or alternate approaches to this framework can be utilize,as necessary,to ensure the adequacy of the assessment of product quality,For ease of discussion,a simple dosage form is defined as a solution or an immediate release(IR)solid oral dosage form.,QBR:,Drug Substance,Description and Characterization,What are the nomenclature,molecular structure,molecular formula,and molecular weight?,What are the,pKa,aqueous solubility(as function of pH),partition coefficient,polymorphism,hygroscopicity,and melting points?,Control of Drug Substance,Appearance and Identification,Are the specifications for appearance and identification appropriate?,Assay,Is the proposed drug substance assay limit acceptable?,Is the analytical method validated and stability-indicating?,Impurities and Residual Solvents,Are all the possible impurities accounted for?,What is the justification for the impurity acceptance limits?,Are the analytical methods validated and suitable for their intended function?,Additional Specifications,Based on the review of the drug product and manufacturing process are,specification(s,)required on particle size,solid state form,moisture content,or other properties of the drug substance and why?,For each additional specification:What is the justification for the acceptance limit?Is it suitable for its intended function?,QBR:,Drug Product,Description and Composition,What are the components and composition of the final product?What is the function of each excipient?,Do any excipients exceed IIG limits in the context of maximum daily dose and route of administration?,If product is an NTI drug or a non-simple dosage form,Are there significant differences between this formulation and the RLD that present potential concerns with respect to product performance?,Control of Excipients,What are the specifications for the inactive ingredients and are they appropriate per their intended function?,Simple Dosage Form:Either a solution or an IR solid oral dosage form,QBR:,Drug Product(Continued),Manufacture,For all products,Does the batch formula accurately reflect the drug product composition?If not,what are the differences and the justifications(e.g.potency adjustment,overage,excess coating solution,etc.)?,If product is not a solution,What are the key unit operations in the drug product manufacturing process?,Are in-process tests identified by the sponsor appropriate?,What is the difference in size between commercial scale and biobatch and do they use the same unit operations?,If product is an NTI drug or a non-simple dosage form,What are the critical steps in the manufacturing process?,What are the in-process tests/controls that ensure each critical step is successful?,In the proposed scale up process what operating conditions will be adjusted to ensure the product meets all in-process and final product specifications?,Why do you believe the sponsor has demonstrated a reasonable plan to scale up the process?,QBR:,Drug Product(Continued),Control of Drug Product,Identity,Is the specification for the identity of the drug product appropriate?,Assay and Uniformity,Are the proposed drug assay limits acceptable?,Is the assay method validated and stability-indicating?,How is the content uniformity evaluated?Is it acceptable?,Impurities/Degradation Products,Are the degradation products and their origins adequately described?,What is the justification for the acceptance limits on degradation products?,Are the analytical methods validated and suitable for their intended function?,Dissolution,What are the dissolution methods and acceptance criteria and how were they selected?,What is the significant role of dissolution testing for this product?,Additional Specifications,Are there additional specifications that are required to ensure the product will perform as labeled and why?,For each additional specification:What is the justification for the acceptance limit?Are the analytical methods validated and suitable for their intended function?,QBR:,Drug Product(Continued),Reference Standard,Are there a qualification report and COA provided for the reference standard or is this material purchased from an appropriate source?,Container/Closure System,Has the container/closure system been used in a previously approved product or otherwise qualified for this dosage form?,What specific container/closure attributes are necessary to ensure product performance?,Drug Product Stability,Data,What stability data has been submittedHas the sponsor provided stability data for the drug product packaged in the proposed container/closure?,Acceptance limits,Are all attributes that could change over time evaluated in the stability tests?,What are the acceptable limits on these attributes?,Shelf-life recommendation,What is the justification of shelf life?,Is the post-approval stability protocol acceptable?,QBR:,Product Development Report for Complex Dosage Forms and NTI Drugs,Drug Substance,Which properties or physical chemical characteristics of the drug substance affect drug product performance?,Excipients,Is there any evidence of incompatibility between the excipients and drug substance?,Formulation,What is the formulation intended to do?,What mechanism does it use to accomplish this?,Were any other formulation alternatives investigated and how did these perform?,Were any formulation optimization or sensitivity studies carried out for variations in composition around the final formulation?Were these studies sufficient to establish a design space for formulation composition?,Is the formulation design consistent with the dosage form classification in the label?,Drug Product,What are the critical quality attributes that ensure the product will perform as labeled?,QBR:,Process Development Report,Process Description,Why was this manufacturing process selected for this drug product?,Were alternative unit operations investigated by process development studies?,Critical Steps and Scale Up,How were the critical steps in the process identified?,What are the critical process parameters for each critical step and how were they identified,monitored and/or controlled?,Were process development studies that varied starting materials or operating parameters conducted?Were these studies sufficient to establish a desig